RecruitingPhase 3NCT07304284

Trial to Evaluate Immunogenicity Non-Inferiority, Safety and Lot-to-Lot Consistency of Biovac OCV-S to Euvichol®-Plus

Studying Cholera

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
International Vaccine Institute
Principal Investigator
Tarun Saluja, MD
International Vaccine Institute
Intervention
Experimental: Biovac OCV-S (inactivated whole-cell monovalent (O1) oral cholera vaccine)(biological)
Enrollment
2824 enrolled
Eligibility
1-45 years · All sexes
Timeline
20252027

Study locations (5)

Collaborators

BioVac · Medical Research Council, South Africa

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT07304284 on ClinicalTrials.gov

Other trials for Cholera

Additional recruiting or active studies for the same condition.

See all trials for Cholera

← Back to all trials